Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Recruiting · NCT06500273 · Registry updated 2026-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT06500273 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Allogene Therapeutics | 5 |
| Foresight Diagnostics, Inc. | 2 |
| Natera, Inc. | 45 |
85 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.